Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron shares poised for rebound: Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:19pm CET

(Reuters) - Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
02/23REGENERON PHARMACEUTICALS : Accelerated Cure Project Launches Collaborative Rese..
AQ
02/23STUDIES IN THE AREA OF BREAST CANCER : Novel targets...
AQ
02/15REGENERON PHARMACEUTICALS : Patent Application Titled "Novel Cho Integration Sit..
AQ
02/15REGENERON PHARMACEUTICALS : Patent Issued for Production of Fertile XY Female Mi..
AQ
02/14NASDAQ 100 MOVERS : Regn, bidu
AQ
02/14REGENERON PHARMACEUTICALS : Announces Appointment of Marion McCourt as Senior Vi..
AQ
02/12REGENERON PHARMACEUTICALS : Today’s Research Reports on Trending Tickers: Regene..
AC
02/12REGENERON PHARMACEUTICALS : Announces Appointment of Marion McCourt as Senior Vi..
PR
02/08REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
02/08REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Inc. Deta..
AQ
More news
News from SeekingAlpha
02/23Some Thoughts On The Continued Negative Media For Regeneron 
02/22Regeneron's Eylea sees uptick in side effects, cause unknown 
02/21UNDERVALUED AND ATTRACTIVE : Pick Up Novartis In 2018 
02/21Premarket analyst action - healthcare 
02/19Regeneron Annual Report, Earnings Forecast And Stock Valuation 
Financials ($)
Sales 2018 6 368 M
EBIT 2018 2 492 M
Net income 2018 1 711 M
Finance 2018 3 230 M
Yield 2018 -
P/E ratio 2018 21,68
P/E ratio 2019 18,55
EV / Sales 2018 4,85x
EV / Sales 2019 4,09x
Capitalization 34 113 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 420 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-16.00%34 113
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343
BLUEBIRD BIO INC12.97%10 168